Companies / AgomAb Therapeutics NV / Activity
Activity — AgomAb Therapeutics NV
9 moves.
Top impactInsider · CEO movesInsider · biggest buysInsider · biggest sellsInstitution · biggest movesInstitution · new positions
| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Q1 2026 as of | Sanofi 13F manager | New | Common stock | $29.19M | +2.8M | 2,783,096 8.15% of shares | medium |
| Q1 2026 as of | Federated Hermes Inc 13F manager | New | Common stock | $16.97M | +1.6M | 1,618,000 4.74% of shares | medium |
| Q1 2026 as of | Perceptive Advisors LLC 13F manager | New | Common stock | $6.29M | +600K | 600,000 1.76% of shares | medium |
| Q1 2026 as of | Millennium Management LLC 13F manager | New | Common stock | $999.0K | +95K | 95,233 0.28% of shares | low |
| Q1 2026 as of | Laurion Capital Management LP 13F manager | New | Common stock | $524.5K | +50K | 50,000 0.15% of shares | low |
| Q1 2026 as of | Sectoral Asset Management Inc 13F manager | New | Common stock | $477.3K | +44K | 43,500 0.13% of shares | low |
| Q2 2026 as of | Quadrature Capital Ltd 13F manager | New | Common stock | $265.6K | +20K | 20,461 0.06% of shares | low |
| Q1 2026 as of | D. E. Shaw & Co., Inc. 13F manager | New | Common stock | $160.8K | +15K | 15,326 0.04% of shares | low |
| Q1 2026 as of | Two Sigma Investments, LP 13F manager | New | Common stock | $149.4K | +14K | 14,241 0.04% of shares | low |